Factor D Inhibitors for Complement-Mediated AMD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical therapies are inadequate for treating or preventing complement-mediated diseases such as age-related macular degeneration, particularly the dry form and neovascular AMD, which often lead to legal blindness despite treatment with anti-VEGF agents like Lucentis.
Innovation Solution
Development of compounds that modulate and inhibit the alternative complement pathway by targeting Factor D, a key enzyme in this pathway, to suppress amplification of the complement system and prevent disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-VEGF agents like Lucentis are used to treat AMD, then vascular leakage and abnormal blood vessel growth are suppressed, but the therapy remains inadequate for preventing complement-mediated diseases and vision loss
Solution Approach 1:
The patent segments the complement system into distinct pathways (classical, lectin, and alternative pathways) and targets specific components within these pathways. By developing inhibitors that act on individual complement components rather than the entire system, the treatment can be tailored to specific disease mechanisms while avoiding broad immunosuppression.
Solution Approach 2:
The patent introduces small molecule inhibitors as intermediary substances that block the interaction between complement components. These inhibitors act as mediators that prevent the formation of C3-convertase and C5-convertase complexes, thereby interrupting the complement cascade without directly affecting the underlying disease pathology.
2Reliability
If the complement system is fully activated to fight infection, then immune response is enhanced, but harmful amplification occurs leading to tissue damage and disease progression
Solution Approach 1:
The patent applies local quality by enabling selective inhibition of complement activation at specific sites where pathological amplification occurs, rather than systemically suppressing the entire complement system. This allows the immune system to maintain protective functions in healthy tissues while preventing damage in affected areas.
Solution Approach 2:
The patent converts the harmful uncontrolled amplification of the complement system into a beneficial controlled response. By using small molecule inhibitors to regulate complement activation, the therapy harnesses the protective immune functions of the complement system while preventing the harmful effects of excessive activation, effectively turning a double-edged sword into a controlled protective force.
3Reliability
If Factor D activity is inhibited to block alternative pathway amplification, then complement-mediated disease progression is prevented, but the plasma concentration target is very low (about 1.8 μg/mL)
Solution Approach 1:
The patent applies parameter changes by developing inhibitors with extremely high binding affinity for Factor D, allowing effective blockade of this low-concentration protein. By optimizing the pharmacological parameters of the inhibitor (such as dissociation constant and binding kinetics), the therapy achieves potent inhibition despite the target's low plasma concentration.
Solution Approach 2:
The patent replaces the natural regulatory mechanisms that normally control Factor D activity with a pharmacological substitute. Instead of relying on the body's endogenous control systems, small molecule inhibitors provide an external regulatory mechanism that can precisely control Factor D activity regardless of its low concentration, effectively substituting natural regulation with drug-mediated control.
Data Source
AI summary
The present invention provides a compound of formula I:a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.